Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;9(6):822-835.
doi: 10.1038/s41551-024-01259-7. Epub 2024 Nov 28.

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses

Affiliations

Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses

Reza Rezaei et al. Nat Biomed Eng. 2025 Jun.

Abstract

Optimization of oncolytic viruses for therapeutic applications requires the strategic removal or mutagenesis of virulence genes alongside the insertion of transgenes that enhance viral replication, spread and immunogenicity. However, the complexity of many viral genomes and the labour-intensive nature of methods for the generation and isolation of recombinant viruses have hindered the development of therapeutic oncolytic viruses. Here we report an iterative strategy that exploits the preferential susceptibility of viruses to certain antibiotics to accelerate the engineering of the genomes of oncolytic viruses for the insertion of immunomodulatory cytokine transgenes, and the identification of dispensable genes with regard to replication of the recombinant oncolytic viruses in tumour cells. We applied the strategy by leveraging insertional mutagenesis via the Sleeping Beauty transposon system, combined with long-read nanopore sequencing, to generate libraries of herpes simplex virus type 1 and vaccinia virus, identifying stable transgene insertion sites and gene deletions that enhance the safety and efficacy of the viruses.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

References

    1. Kelly, E. & Russell, S. J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651–659 (2007). - PubMed - DOI
    1. Lemos de Matos, A., Franco, L. S. & McFadden, G. Oncolytic viruses and the immune system: the dynamic duo. Mol. Ther. Methods Clin. Dev. 17, 349–358 (2020). - PubMed - PMC - DOI
    1. Xu, L., Sun, H., Lemoine, N. R., Xuan, Y. & Wang, P. Oncolytic vaccinia virus and cancer immunotherapy. Front. Immunol. 14, 1324744 (2023). - PubMed - DOI
    1. Pelin, A., Boulton, S., Tamming, L. A., Bell, J. C. & Singaravelu, R. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity. Expert Opin. Biol. Ther. 20, 1083–1097 (2020). - PubMed - DOI
    1. De Graaf, J. F., de Vor, L., Fouchier, R. A. M. & van den Hoogen, B. G. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 41, 28–39 (2018). - PubMed - PMC - DOI

LinkOut - more resources